Compare PHAT & IDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAT | IDT |
|---|---|---|
| Founded | 2018 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2019 | N/A |
| Metric | PHAT | IDT |
|---|---|---|
| Price | $11.56 | $51.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $19.50 | N/A |
| AVG Volume (30 Days) | ★ 898.5K | 108.9K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.47% |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $83.18 | $1.99 |
| Revenue Next Year | $61.43 | N/A |
| P/E Ratio | ★ N/A | $15.10 |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $2.21 | $45.07 |
| 52 Week High | $18.31 | $71.12 |
| Indicator | PHAT | IDT |
|---|---|---|
| Relative Strength Index (RSI) | 39.53 | 63.15 |
| Support Level | $10.65 | $50.02 |
| Resistance Level | $12.77 | $52.24 |
| Average True Range (ATR) | 0.87 | 1.21 |
| MACD | 0.09 | 0.38 |
| Stochastic Oscillator | 14.01 | 99.01 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.